[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Algemeen Ziekenhuis Maria Middelares\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":262},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,74,92,112,156,186,212,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645347","auricular-vagus-nerve-stimulation-in-patients-with-high-impact-chronic-low-back-pain-100645347",false,"NCT07681336","Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain","Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain - a Prospective, Interventional, Open, Randomized, Controlled, Single-center Trial","VIVO","Inclusion Criteria:\n\n* Male or female patients aged ≥ 30 and ≤ 60 years;\n* High impact lumbar or lumbosacral myofascial\u002Fmusculoskeletal chronic (\\> 6 months) low back pain that is moderate to severe (defined as average pain over the last 4 weeks ≥ 5 on the NRS at baseline);\n* Normal function of lumbosacral nerves based on clinical assessment;\n* Unresponsive\u002Fintolerance (meaning insufficient pain reduction or intolerance) to oral pharmacotherapy (World Health Organization (WHO) grade II);\n* ODI 21-80 at baseline;\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic low back pain (trauma, fracture, tumor, infection, documented severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions);\n* Indication for back surgery;\n* Radicular pain;\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, etc.);\n* Opioid analgesic therapy;\n* Underwent other physical therapy modalities, including TENS, ultrasound, infiltration, RF-treatment, 2 weeks before screening;\n* History of Vagus Nerve Stimulation or ear stimulation;\n* History of vasovagal syncope;\n* BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher);\n* Hemophilia;\n* Documented autonomic disorders;\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure at baseline (systolic blood pressure (SBP) \\> 160 mmHg);\n* Major psychiatric comorbidity (HADS ≥ 10 on each subscale at baseline);\n* Other serious clinically relevant co-morbidity, florid malignant conditions or neurological diseases;\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies;\n* Use of prescription blood thinners, e.g., oral anticoagulants (marevan, sintrom, marcoumar), noval oral anticoagulants (pradaxa, xarelto, eliquis, lixiana), anti-platelet medication (asaflow);\n* Infection, eczema, or psoriasis at application site (ear and neck);\n* Numbed and desensitized skin at the application site (ear and neck);\n* Serious drug-related behavioral issues (e.g., alcohol dependency, illegal substance abuse) in the last 6 months;\n* Pregnant, parturient or breast-feeding women;\n* Active implantable device (e.g. cardiac pacemaker, defibrillator, cochlear implant, neurostimulator like Spinal Cord Stimulation or Peripheral Nerve Stimulation) ;\n* Currently participating in another interventional clinical trial or participated over the last 3 months;\n* Patients who are unable to sufficiently speak and write in the Dutch language;\n* Mental and physical impairments that represent a source of risk for handling the device;\n* Patients under legal protection (curatorship, guardianship);\n* Patients subject to a legal protection measure;\n* An adult who is incapable or unable to give consent.","ALL","30 Years","60 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether auricular vagus nerve stimulation using the VIVO® device can improve function and reduce pain in adults with high-impact chronic low back pain when added to standard medical care. It will also assess the safety and usability of this therapy.\n\nThe study includes adult patients aged 30 to 55 years who have had moderate to severe chronic low back pain for more than 6 months and who did not experience sufficient relief with standard pain treatments.\n\nThe main questions this study aims to answer are:\n\n* Does adding the VIVO® device to standard care help people function better in daily life?\n* Does the VIVO® device help lower pain and improve wellbeing, sleep, and quality of life?\n\nResearchers will compare standard care plus VIVO® to standard care alone to see if the device improves outcomes.\n\nStandard care may include medication, physiotherapy, or other usual treatments.\n\nThe main outcome is the change in disability (measured using the Oswestry Disability Index) after 6 weeks of treatment.\n\nParticipants will:\n\n* Attend a baseline visit where medical history, physical examination, and questionnaires about pain, function, mood, sleep, and quality of life are collected;\n* Be randomly assigned to one of the two treatment groups;\n* Attend weekly visits for 6 weeks during the treatment phase;\n* Keep a diary of their pain levels and any treatments or medications used;\n* Complete questionnaires about pain, function, sleep, and wellbeing during the study.\n\nParticipants in the intervention group will:\n\nReceive a VIVO® wearable device applied to the ear, which delivers electrical stimulation to the vagus nerve; Use the device continuously over 6 weeks, with weekly replacement and adjustment of stimulation settings; Be able to adjust the stimulation intensity themselves using a handheld device.\n\nAfter the treatment period, all participants will be followed for 12 months, with additional visits or contacts to assess long-term effects, safety, and sustainability of the treatment.",[28],"Chronic Low Back Pain",[30,31],"auricular vagus nerve stimulation","VIVO device","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2026-03-04",{"date":40,"type":22},"2028-09",{"name":42,"class":43},"Algemeen Ziekenhuis Maria Middelares","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100483446","robotic-versus-open-comparison-in-the-surgical-treatment-of-wide-abdominal-wall-hernias-rocstar-100483446","NCT05575141","Robotic Versus Open Comparison in the Surgical Treatment of Wide Abdominal Wall heRnias (ROCSTAR)","Robotic Versus Open Comparison in the Surgical Treatment of Wide Abdominal Wall Hernias: a Multicenter International Randomized Controlled Trial","ROCSTAR","Inclusion Criteria:\n\n\\- All patients requiring treatment of a wide ventral incisional hernia (of more than 8 centimetres in width)\n\nExclusion Criteria:\n\n* Pregnant or suspected pregnancy\n* Not-curatively treated malignancy, with life expectancy less than 24 months\n* Patients unable to give informed consent or complete study specific questionnaires\n* Emergency surgery\n* Primary ventral hernia repair\n* Exclusively lateral hernias not involving the midline\n* Incisional hernia repair after open abdomen or enterocutaneous fistula\n* Active wound infection\n* Previous anterior or posterior component separation\n* Patients with an existing ostomy\n* Patients with a life expectancy of less than 24 months\n* Patients suspected of being unable to comply with the study protocol","18 Years",{"count":55,"type":22},100,[25],"In the treatment of ventral incisional hernias, a mesh repair in the retromuscular plane is considered as the gold standard. To allow for adequate medialization of the fascial borders and a complete closure of the defect in case of large incisional hernias, component separation techniques are increasingly being used. When compared to anterior component separation, posterior component separation by transversus abdominis release (TAR) seems to decrease postoperative wound problems. While laparoscopic techniques pose significant difficulties to perform TAR minimally invasively (mainly due to ergonomic and technical reasons), these limitations seem to be overcome by robotic platforms. Initial retrospective patient series report on significantly shorter postoperative hospital stay and fewer complications after robotic transversus abdominis release (rTAR), when compared to open transversus abdominis release (oTAR). High-quality prospective evidence on rTAR is currently lacking.",[59,60],"Ventral Incisional Hernia","Abdominal Wall Hernia",[60,62,63,64],"robotic TAR (rTAR)","open TAR (oTAR)","transversus abdominis release (TAR)","NOT_YET_RECRUITING","2025-04-10",{"date":68,"type":36},"2025-04-11",{"date":70,"type":22},"2025-07-01",{"date":72,"type":22},"2033-01-01",{"name":42,"class":43},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":44},"100355203","conventional-versus-robot-assisted-laparoscopic-inguinal-hernia-repair-100355203","NCT03904888","Conventional Versus Robot Assisted Laparoscopic Inguinal Hernia Repair","Inclusion Criteria:\n\n* adult patients presenting with a bilateral inguinal hernia planned for a minimal invasive laparoscopic repair\n\nExclusion Criteria:\n\n* Age below 18 years\n* unilateral groin hernia repair\n* incarcerated hernias\n* open hernia repair\n* no informed consent\n* pregnant women\n* ASA score 4 or more\n* patient included in another study.",{"count":81,"type":22},200,[25],"Evaluate the early postoperative course of patients undergoing laparoscopic inguinal hernia repair with either a conventional or a robot assisted approach and with or without the injection of the trocar wounds with a local anesthetic.",[85],"Inguinal Hernia",{"date":68,"type":36},{"date":88,"type":36},"2019-09-23",{"date":90,"type":22},"2029-12",{"name":42,"class":43},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100269049","laparoscopic-groin-hernia-repair-by-a-3d-endolap-visible-mesh-with-or-without-liquiband-fix-8-mesh-fixation-100269049","NCT02781870","Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible Mesh With or Without LiquiBand Fix 8 Mesh Fixation","Randomized Single-center Study on Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible With and Without LiquiBand Fix 8 Mesh Fixation","Inclusion Criteria:\n\n* adult patients presenting with primary unilateral inguinal hernia\n* patients planed for a laparoscopic repair\n\nExclusion Criteria:\n\n* Age below 18 years\n* recurrent or incarcerated hernias\n* open hernia repair and bilateral hernias\n* concomitant repair of another kind of abdominal hernia\n* combined surgical procedures\n* no informed consent\n* pregnant women\n* ASA score 4 or more\n* contra-indications for MRI scans.","80 Years",{"count":55,"type":22},[25],"This study aims to visualize the implanted mesh in vivo by MRI in 20 patients at 1 month and 12 months post-operatively. Moreover, we want to evaluate the safety and efficiency of non-penetration mesh fixation techniques using pre-designed ENDOLAP 3D visible mesh placement versus mesh fixation using a synthetic LiquiBand Fix 8 glue for laparoscopic treatment of groin hernias.\n\nA total of 100 male and female patients will be entered in the trial in Maria Middelares Ghent, for which an inclusion period of 24 months is anticipated. Four surgeons of the department of surgery will screen all eligible consecutive patients for inclusion in the study. They will inform all patients about the surgery and the follow-up with MRI scan thereafter.",[104,105],"Hernia","Recurrence",{"date":68,"type":36},{"date":108,"type":36},"2016-05-09",{"date":110,"type":22},"2027-08",{"name":42,"class":43},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":137,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":44},"100580294","high-resolution-pet-ct-specimen-imaging-for-the-perioperative-visualization-of-resection-margins-100580294","NCT06835426","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins: an Exploratory Pilot Study","A. Inclusion Criteria:\n\n* able to understand treatment protocol and informed consent form\n* estimated by the investigator to be compliant for study participation\n\n  1\\. Fulfilling all group-specific inclusion criteria:\n* confirmed breast cancer with an indication to undergo breast conserving surgery\n* confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;\n* confirmed thyroid lesion with an indication to undergo resective surgery;\n* confirmed parathyroid adenoma with an indication to undergo resective surgery;\n* suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;\n* suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;\n* suspected lesion in the head \\& neck region with an indication to undergo resective surgery;\n* confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;\n* patients undergoing biopsy after metabolic active lesions were detected on a PET scan.\n* suspected neuro-endocrine malignancies with an indication to undergo resective surgery.\n* suspected brain tumor with an indication to undergo resective surgery.\n* Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.\n* suspected malignant thoracovascular lesions with an indication to undergo resective surgery\n\nB. Exclusion Criteria:\n\n* general or local contra-indications for resective surgery;\n* in case of FDG-based PET tracers: a blood glucose level over 200 mg\u002FdL on the day of surgery;\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.",{"count":120,"type":22},150,[25],"These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this.\n\nPositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner.\n\nThe overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.",[124,125,126,127,128,129,130,131,132,133,134,135,136],"Breast Carcinoma","Prostate Cancer Surgery","Thyroid Cancer","Parathyroid Adenomas","Skin Cancer","Genitourinary Cancer","Head and Neck Cancer","Hepatobiliary Cancers","Metabolic Abnormality","Neuro Endocrine Tumours","Brain Tumours","Gastro Intestinal Cancer","Thoracoscopic Surgery",[138,139,140,141,142,143,144,145,146,147],"resective surgery","perioperative high-resolution PET-CT specimen imaging","breast cancer","Prostate cancer","thyroid cancer","parathyroid cancer","head and neck cancer","neuro-endocrine malignancies","genitourinary malignacies","thoracovascular malignancies","2025-02-14",{"date":150,"type":36},"2025-02-19",{"date":152,"type":36},"2023-08-06",{"date":154,"type":22},"2027-06-30",{"name":42,"class":43},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":164,"minAge":53,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":44},"100522250","phase-4-goal-directed-fluid-therapy-during-deep-inferior-epigastric-perforator-diep-free-flap-breast-reconstruction-100522250","NCT06080178","Goal-directed Fluid Therapy During Deep Inferior Epigastric Perforator (DIEP) Free Flap Breast Reconstruction","Goal-directed Fluid Therapy During Deep Inferior Epigastric Perforator (DIEP) Free Flap Breast Reconstruction - a Randomised Controlled Trial","GDFT DIEP-flap","Inclusion Criteria:\n\n* Female adult patients, between 18 and 70 years of age\n* Patients scheduled for DIEP free flap breast reconstruction\n* Signed written informed consent form (ICF)\n\nExclusion Criteria:\n\n* present atrial fibrillation (AF)\n* heart failure New York Heart Association (NYHA) classification 2 or higher\n* chronic kidney disease (CKD) stage 3B or higher\n* American Society of Anesthesiologists (ASA) classification III or higher\n* known allergy to study specific medication\n* participation in another clinical trial\n* Inability of the patient to understand Dutch sufficiently\n* Patients who are pregnant or breastfeeding","FEMALE","70 Years",{"count":167,"type":22},82,[169],"PHASE4","Adequate free flap perfusion during Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction surgery requires maintaining blood pressure above 100 mmHg and avoiding excessive fluid administration. This study aims to determine whether the use of a measurement of preload dependency (Pulse Pressure Variation = PPV), can guide fluid therapy and if it decreases the risk of flap oedema. For this purpose, two fluid management strategies will be compared:\n\n* Static intraoperative fluid management: Administration of crystalloid fluids is limited to 5ml\u002Fkg\u002Fh\n* Dynamic intraoperative fluid management: Crystalloid fluids are only administered if PPV exceeds 12% The purpose of this study is to compare the static and dynamic (= targeted) fluid strategy and to evaluate the effect on flap oedema and flap perfusion.",[172],"Hypotension During Surgery",[174,175,176,177],"arterial hypotension","postoperative hypotension","Goal-directed Fluid Therapy","DIEP free flap breast reconstruction","2025-01-27",{"date":180,"type":36},"2025-01-28",{"date":182,"type":36},"2023-11-23",{"date":184,"type":22},"2026-10-01",{"name":42,"class":43},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":44},"100573159","rapid-move-following-outpatient-surgery-safety-and-patient-characteristics-100573159","NCT06742658","Rapid Move Following Outpatient Surgery: Safety and Patient Characteristics","A Retrospective Study on the Safety of the Rapid Move Following Outpatient Surgery and the Characteristics of Patients in the Rapid Move","OUTSIDE","Inclusion Criteria:\n\n* Patients aged 15 years or older;\n* Patients who went to the Rapid Move after their outpatient procedure. Eligible procedures are: gastroscopy, coloscopy, vasectomy, scrotal surgery, circumcision or other minor penile surgery, intravesical Botox, insertion or removal of eardrum tubes in adults, sinus irrigation in adults, sleep endoscopy, bronchoscopy, removal of osteosynthetic material in the lower leg and foot, and tooth extraction (including wisdom teeth) and upper-forearm orthopedic surgery (excluding prosthetic surgery).\n\nExclusion Criteria:\n\n* Inpatients defined as a patient who is formally admitted (or \"hospitalized\") to an institution for treatment and\u002For care and stays for a minimum of one night in the hospital or other institution providing inpatient care;\n* Patients undergoing emergency procedures.","15 Years",{"count":196,"type":22},1500,"OBSERVATIONAL","A descriptive, retrospective cohort study will be conducted to gain insight in the safety of the Rapid Move. The trial will include a group of Rapid Move patients, who were transferred to the Rapid Move after their outpatient surgery and subsequently discharged home. The Rapid Move is a short-stay PACU where patients recover from anaesthesia, are continuously monitored, and prepared for discharge within an hour after surgery.",[200],"Postoperative Recovery",[202,203,204],"Postoperative recovery","PACU","Rapid Move","2024-12-18",{"date":207,"type":36},"2024-12-19",{"date":209,"type":22},"2025-12",{"date":209,"type":22},{"name":42,"class":43},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":220,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":235},"100562157","setup-study-for-hugotm-ras-inguinal-hernia-repair-100562157","NCT06599515","SetUp Study for HugoTM RAS Inguinal Hernia Repair","A Multicenter Comparative Prospective Observational Cohort Study About Robot-assisted Laparoscopic Inguinal Hernia Repair Using Two Different Robotic Systems","SUSHI","Inclusion Criteria: All patients planned for a minimal invasive (robotic assisted laparoscopic) inguinal hernia repair during the study period will be invited to take part in the study. Both unilateral and bilateral hernias will be included.\n\nExclusion Criteria:\n\n* Recurrent hernias after previous preperitoneal mesh placement.\n* Inguinal hernias after abdominal prostatectomy.\n* Pregnancy.\n* Emergency surgery.\n* Age below 18 years.\n* Absence of informed consent.",true,{"count":55,"type":22},[25],"The goal of this observational cohort study is to evaluate the evolution of the operative time in performing robotic assisted laparoscopic inguinal hernia repair (rTAPP) during the learning curve of the first 50 patients using the HugoTM Ras (Medtronic) robotic system using the setup guide.\n\nResearchers will compare to the operative time for rTAPP of 50 patients by the same surgeon in another hospital using the daVinci Xi (Intuitive Surgical) robotic system.",[85],[226],"robot-assisted laparoscopic inguinal hernia repair","2024-09-13",{"date":229,"type":36},"2024-09-19",{"date":231,"type":36},"2023-09-15",{"date":233,"type":22},"2025-12-31",{"name":42,"class":43},2,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":44},"100544514","phase-4-interpectoral-pectoserratus-plane-block-for-minimally-invasive-aortic-valve-replacement-via-right-anterior-minithoracotomy-100544514","NCT06369870","Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy","Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy: a Single Centre, Prospective, Double-blind, Randomized Controlled Superiority Trial","PAINCARE","Inclusion Criteria:\n\n* Adult patients (18 years of age or older);\n* Patients scheduled for minimally invasive aortic valve replacement via right anterior minithoracotomy;\n* Patients with American Society of Anesthesiologists (ASA) physical status classification II, III or IV;\n* Patients with European System for Cardiac Operative Risk Evaluation (EuroSCORE) 2 ≤ 4%;\n* Patient has given written, free and informed consent.\n\nExclusion Criteria:\n\n* BMI \\> 35;\n* Patients under legal protection (curatorship, guardianship);\n* Patients subject to a legal protection measure;\n* An adult who is incapable or unable to give consent;\n* Patients requiring emergency surgery within 24 hours;\n* Chronic opioid use (\\> 3 administrations per week or continuous transdermal therapy, longer than the last 3 months);\n* Patients known with chronic pain;\n* Patients known with an allergy to levobupivacaine or drugs used as standard of care, including amongst others piritramide, dexamethasone, propofol, remifentanil, rocuronium, acetaminophen, ondansetron;\n* Patients who receive medication that could possibly interact with levobupivacaine (mexiletine, ketoconazole, theophylline);\n* Patients who took monoamine oxidase (MAO) inhibitors within the last 2 weeks before surgery;\n* Patients with chronic renal failure (dialysis dependent, estimated glomerular filtration rate (eGFR) \\\u003C 30 ml.min-1.(1,73 m²)-1) ;\n* Patients with severe hepatic impairment (Model for End-Stage Liver Disease (MELD) score ≥ 20);\n* Patients with preoperative cognitive dysfunction (Mini Mental State Examination (MMSE) score \\\u003C 24);\n* Patients with uncontrolled epilepsy;\n* Patients with severe arterial hypotension (Systolic Arterial Pressure (SAP) \\\u003C 90 mmHg, cardiogenic shock);\n* Patients who simultaneously participate in another interventional clinical trial;\n* Soft tissue infection in the area of the procedure;\n* Patients who are pregnant, parturient or breast-feeding women;\n* Patients who are unable to sufficiently speak and write in the Dutch language.",{"count":245,"type":22},144,[169],"The goal of this clinical trial is to evaluate the analgesic effect of locoregional anaesthesia, specifically the interpectoral pectoserratus plane (IPP-PSP) block, in comparison to a placebo (sham block) after Aortic Valve Replacement via Right Anterior Minithoracotomy (AVR-RAT). The main question the trial aims to answer is: Can the IPP-PSP block effectively reduce opioid consumption within the first 48 hours after AVR-RAT surgery? The purpose is to understand the impact of the IPP-PSP block on postoperative pain. Therefore, the aim is to investigate the influence of the IPP-PSP block on the amount of pain medication administered during the patients' first 48 hours after surgery.\n\nParticipants, who are scheduled for AVR-RAT surgery, will be randomly assigned to receive either the IPP-PSP block or the sham block. Researchers will compare opioid consumption among other outcomes, including differences in pain scores, incidence of nausea and vomiting, quality of recovery, quality of life, and the length of hospital stay between the two groups.\n\nPatients will be monitored during their hospitalization, and a follow-up phone call will be conducted 30 days after surgery.",[249],"Analgesic Effect",[251,252,253,254],"interpectoral-pectoserratus plane block","aortic valve replacement via right anterior minithoracotomy","IPP-PSP block","AVR-RAT","2024-09-05",{"date":229,"type":36},{"date":258,"type":36},"2024-09-01",{"date":260,"type":22},"2027-12",{"name":42,"class":43},""]